Heart valve study seeks best blood thinner to prevent clots and bleeding
NCT ID NCT07677410
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests two blood-thinning strategies in people with severe aortic regurgitation who have had a new heart valve placed without open surgery. Participants receive either daily aspirin for a year or warfarin for six months followed by aspirin. The goal is to see which approach better prevents serious events like stroke, blood clots, and major bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin and Warfarin
What this could lead to
If aspirin proves superior, it could simplify post-procedure care and reduce bleeding risks for patients with severe aortic regurgitation after valve replacement.
What could go wrong
This is a mid-stage trial; results may not apply to all patients, and warfarin carries bleeding risks while aspirin may not prevent clots as effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC REGURGITATION DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••